Universal Vision Biotechnology Co Ltd - Asset Resilience Ratio
Universal Vision Biotechnology Co Ltd (3218) has an Asset Resilience Ratio of 21.73% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Universal Vision Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Universal Vision Biotechnology Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Universal Vision Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Universal Vision Biotechnology Co Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.32 Billion | 21.73% |
| Total Liquid Assets | NT$1.32 Billion | 21.73% |
Asset Resilience Insights
- Good Liquidity Position: Universal Vision Biotechnology Co Ltd maintains a healthy 21.73% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Universal Vision Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Universal Vision Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fresenius SE & Co. KGaA
XETRA:FRE |
Medical Care Facilities | 9.40% |
|
Apollo Hospitals Enterprise Limited
NSE:APOLLOHOSP |
Medical Care Facilities | 14.32% |
|
Sienna Senior Living Inc
TO:SIA |
Medical Care Facilities | 0.09% |
|
Mitra Keluarga Karyasehat Tbk PT
JK:MIKA |
Medical Care Facilities | 9.01% |
|
Chularat Hospital Public Company Limited
BK:CHG |
Medical Care Facilities | 1.13% |
|
Hospital Mater Dei S.A
SA:MATD3 |
Medical Care Facilities | 0.63% |
|
Lippo Karawaci Tbk
JK:LPKR |
Medical Care Facilities | 0.51% |
|
ARRAIL GROUP LTD.
F:I1D |
Medical Care Facilities | 17.40% |
Annual Asset Resilience Ratio for Universal Vision Biotechnology Co Ltd (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Universal Vision Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.73% | NT$1.32 Billion ≈ $41.71 Million |
NT$6.09 Billion ≈ $191.97 Million |
-2.75pp |
| 2024-12-31 | 24.48% | NT$1.41 Billion ≈ $44.44 Million |
NT$5.76 Billion ≈ $181.56 Million |
+13.21pp |
| 2023-12-31 | 11.27% | NT$578.36 Million ≈ $18.22 Million |
NT$5.13 Billion ≈ $161.64 Million |
-1.52pp |
| 2022-12-31 | 12.80% | NT$576.62 Million ≈ $18.17 Million |
NT$4.51 Billion ≈ $141.96 Million |
-0.69pp |
| 2021-12-31 | 13.49% | NT$505.81 Million ≈ $15.94 Million |
NT$3.75 Billion ≈ $118.13 Million |
-1.08pp |
| 2020-12-31 | 14.57% | NT$461.75 Million ≈ $14.55 Million |
NT$3.17 Billion ≈ $99.85 Million |
+1.77pp |
| 2019-12-31 | 12.80% | NT$338.97 Million ≈ $10.68 Million |
NT$2.65 Billion ≈ $83.40 Million |
-4.29pp |
| 2018-12-31 | 17.09% | NT$358.41 Million ≈ $11.29 Million |
NT$2.10 Billion ≈ $66.06 Million |
+7.87pp |
| 2017-12-31 | 9.22% | NT$184.89 Million ≈ $5.83 Million |
NT$2.00 Billion ≈ $63.15 Million |
-4.85pp |
| 2016-12-31 | 14.07% | NT$245.21 Million ≈ $7.73 Million |
NT$1.74 Billion ≈ $54.91 Million |
+8.04pp |
| 2015-12-31 | 6.03% | NT$113.99 Million ≈ $3.59 Million |
NT$1.89 Billion ≈ $59.54 Million |
-17.19pp |
| 2014-12-31 | 23.22% | NT$418.63 Million ≈ $13.19 Million |
NT$1.80 Billion ≈ $56.79 Million |
-1.52pp |
| 2013-12-31 | 24.75% | NT$337.88 Million ≈ $10.65 Million |
NT$1.37 Billion ≈ $43.02 Million |
+24.03pp |
| 2012-12-31 | 0.72% | NT$9.03 Million ≈ $284.53K |
NT$1.26 Billion ≈ $39.59 Million |
-1.31pp |
| 2011-12-31 | 2.03% | NT$28.10 Million ≈ $885.34K |
NT$1.38 Billion ≈ $43.59 Million |
+1.06pp |
| 2009-12-31 | 0.98% | NT$10.91 Million ≈ $343.60K |
NT$1.12 Billion ≈ $35.22 Million |
-0.04pp |
| 2008-12-31 | 1.01% | NT$11.03 Million ≈ $347.54K |
NT$1.09 Billion ≈ $34.34 Million |
-13.41pp |
| 2007-12-31 | 14.42% | NT$101.63 Million ≈ $3.20 Million |
NT$704.59 Million ≈ $22.20 Million |
-- |
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy analysis, as we… Read more